AR055104A1 - Inhibidores macrociclicos del virus de la hepatitis c - Google Patents
Inhibidores macrociclicos del virus de la hepatitis cInfo
- Publication number
- AR055104A1 AR055104A1 ARP060103306A ARP060103306A AR055104A1 AR 055104 A1 AR055104 A1 AR 055104A1 AR P060103306 A ARP060103306 A AR P060103306A AR P060103306 A ARP060103306 A AR P060103306A AR 055104 A1 AR055104 A1 AR 055104A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- het
- aryl
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Reivindicacion 1: Un compuesto que tiene la formula (1), un N-oxido, sal de adicion, amina cuaternaria, complejo metálico y forma estereoquímicamente isomérica de éste, en el cual: la línea de punto representa un doble enlace opcional C7-8; R1 es arilo o un sistema anular saturado, parcialmente insaturado o completamente insaturado de 5 o 6 miembros o bicíclico heterocíclico de 9 a 12 miembros donde dicho sistema anular contiene un nitrogeno, y en forma opcional uno a tres heteroátomos adicionales seleccionados del grupo que consiste en oxígeno, azufre y nitrogeno, y donde el resto de los miembros del anillo son átomos de carbono; donde dicho sistema anular puede estar sustituido en forma opcional en cualquier átomo de carbono o nitrogeno del anillo con uno, dos, tres o cuatro sustituyentes seleccionados, cada uno en forma independiente, de; cicloalquilo C3-7, arilo, Het, -C(=O)NR5aR5b, -C(=O)R7, -C(=O)OR6a, y alquilo C1-6 sustituido en forma opcional con cicloalquilo C3-7, arilo, Het, -C(=O)NR5aR5b, -NR5aR5b, -C(=O)R7, -NR5aC(=O)R7, -NR5aSOpR8, -SOpR8, -SOpNR5aR5b, -C(=O) OR6, o -NR5aC(=O)OR6a; y donde los sustituyentes en cada átomo de carbono del anillo heterocíclico pueden seleccionarse, además de -OR8, - SR8, halo, polihaloalquilo C1-6, oxo, tio, ciano, nitro, azido, -NR5aR5b, -NR5aC(=O)R7, -NR5aSOpR8, -SOpR8, -SOpNR5aR5b, -C(O)OH, y - NR5aC(=O)OR6a; L es un enlace directo, -O-, -O-alcandiiloC1-4, -O-CO-, -O-C(=O)-NR5a- u -O-C(=O)-NR5a-alcandiiloC1-4; R2 representa hidrogeno, -OR6, -C(O)OR6, -C(O)R7, -C(O)NR5aR5b, -C(O)NHR5c, -NR5aR5b, -NHR5c, -NHSOpNR5aR5b, -NR5aSOpR8, o -B(OR6)2; R3 y R4 son hidrogeno o alquilo C1-6; o R3 y R4 tomados juntos pueden formar un anillo cicloalquilo C3-7; n es 3, 4, 5, o 6; p es 1 o 2; cada R5a y R5b son, en forma independiente, hidrogeno, cicloalquilo, C3-7, arilo, Het, alquilo C1-6 sustituido en forma opcional con halo, alcoxi, C1-6, ciano, polihaloalcoxi C1-6, cicloalquilo C3-7, arilo, o con Het; o R5a y R5b tomados junto con el átomo de nitrogeno al cual están unidos forman pirrolidinilo, piperidinilo, piperazinilo, 4-alquilpiperaziniloC1-6, 4-alquilcarbonoC1-6-piperazinilo y morfolinilo; donde los grupos morfolinilo y piperidinilo pueden estar sustituido en forma opcional con uno o dos radicales alquilo C1-6; R5c es cicloalquilo C3-7, arilo, Het, -O- cicloalquiloC3-7, -O-arilo, -O-Het, alquilo C1-6, o alcoxi C1-6, donde dicho alquilo C1-6 o alcoxi C1-6 pueden estar sustituidos, cada uno en forma independiente, con -C(=O)OR6, cicloalquilo C3-7, arilo, o Het; R6 es hidrogeno; alquenilo C2-6; Het; cicloalquilo C3-7 sustituido en forma opcional con alquilo C1-6; o alquilo C1-6sustituido en forma opcional con cicloalquilo C3-7, arilo o Het; R6a es alquenilo C2-6, cicloalquilo C3-7, Het, o alquilo C1-6 sustituido en forma opcional con cicloalquilo C3-7, arilo or Het; R7 es hidrogeno, alquilo C1-6, cicloalquilo C3-7, o arilo; R8 es hidrogeno, polihaloalquiloC1-6, arilo, Het, cicloalquilo C3-7 sustituido en forma opcional con alquilo C1-6, o alquilo C1-6 sustituido en forma opcional con cicloalquilo C3-7, arilo o Het; arilo como grupo o parte de un grupo es fenilo, naftilo, indanilo o 1,2,3,4-tetrahidronaftilo, cada uno de los cuales puede estar sustituido en forma opcional con uno, dos o tres sustituyentes seleccionados de halo, alquilo C1-6, polihaloalquilo C1-6, hidroxi, alcoxi C1-6, polihaloalcoxi C1-6, alcoxiC1-6-alquiloC1-6, carboxilo, alquilcarbonilo C1-6, alcoxicarbonilo C1-6, ciano, nitro, amino, mono- o dialquilamino C1-6, aminocarbonilo, mono- o dialquilaminocarbonilo C1-6, azido, mercapto, cicloalquilo C3-7, fenilo, piridilo, tiazolilo, pirazolilo, pirrolidinilo, piperidinilo, piperazinilo, 4- alquilpiperaziniloC1-6, 4-alquilcarbonilC1-6-piperazinilo, y morfolinilo; donde los grupos morfolinilo y piperidinilo pueden estar sustituidos en forma opcional con uno o dos radicales alquilo C1-6; y los grupos fenilo, piridilo, tiazolilo, pirazolilo pueden estar sustituidos en forma opcional con 1, 2 o 3 sustituyentes seleccionados, cada uno en forma independiente, de alquilo C1-6, alcoxi C1-6, halo, amino, mono- o dialquilamino C1-6; Het como grupo o parte de un grupo es un anillo heterocíclico saturado, parcialmente insaturado o completamente insaturado de 5 o 6 miembros que contiene 1 a 4 heteroátomos, seleccionado cada uno en forma independiente de nitrogeno, oxígeno y azufre, dicho anillo heterocíclico está condensado en forma opcional con un anillo bencénico, y donde el grupo Het como un todo puede estar sustituido en forma opcional con uno, dos o tres sustituyentes seleccionados, cada uno en forma independiente, del grupo que consiste en halo, alquilo C1-6, polihaloalquilo C1-6, hidroxi, alcoxi C1-6, polihaloalcoxi C1-6, alcoxiC1-6- alquiloC1-6, carboxilo, alquilcarbonilo, C1-6, alcoxicarbonilo C1-6, ciano, nitro, amino, mono- o dialquilamino C1-6, aminocarbonilo, mono- o dialquilaminocarbonilo C1-6, cicloalquilo C3-7, fenilo, piridilo, tiazolilo, pirazolilo, pirrolidinilo, piperidinilo, piperazinilo, 4-alquilpiperaziniloC1-6, 4-alquilcarbonilC1-6-piperazinilo, y morfolinilo; donde los grupos morfolinilo y piperidinilo pueden estar sustituidos en forma opcional con uno o dos radicales alquilo C1-6; y los grupos fenilo, piridilo, tiazolilo, pirazolilo pueden estar sustituidos en forma opcional con 1, 2 o 3 sustituyentes seleccionados, cada uno en forma independiente, de alquilo C1-6, alcoxi C1-6, halo, amino, mono- o dialquilamino C1-6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05107067 | 2005-07-29 | ||
| EP05107413 | 2005-08-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR055104A1 true AR055104A1 (es) | 2007-08-08 |
Family
ID=37036843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060103306A AR055104A1 (es) | 2005-07-29 | 2006-07-28 | Inhibidores macrociclicos del virus de la hepatitis c |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US7989471B2 (es) |
| EP (1) | EP1912995B1 (es) |
| JP (1) | JP5426163B2 (es) |
| KR (1) | KR101074673B1 (es) |
| CN (1) | CN101233137B (es) |
| AP (1) | AP2473A (es) |
| AR (1) | AR055104A1 (es) |
| AT (1) | ATE517902T1 (es) |
| AU (1) | AU2006274858B2 (es) |
| BR (1) | BRPI0614670A2 (es) |
| CA (1) | CA2617095C (es) |
| DK (1) | DK1912995T3 (es) |
| EA (1) | EA014646B1 (es) |
| GT (1) | GT200600341A (es) |
| HK (1) | HK1116772A1 (es) |
| IL (1) | IL188283A (es) |
| JO (1) | JO2768B1 (es) |
| MX (1) | MX2008001395A (es) |
| MY (1) | MY152153A (es) |
| NO (1) | NO20081071L (es) |
| NZ (1) | NZ564541A (es) |
| PE (1) | PE20070221A1 (es) |
| SG (1) | SG163613A1 (es) |
| SI (1) | SI1912995T1 (es) |
| SV (1) | SV2008002639A (es) |
| TW (1) | TWI412534B (es) |
| UY (1) | UY29705A1 (es) |
| WO (1) | WO2007014919A1 (es) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| ES2336009T3 (es) | 2004-01-30 | 2010-04-07 | Medivir Ab | Inhibidores de la ns-3 serina proteasa del vhc. |
| PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| US7935670B2 (en) | 2006-07-11 | 2011-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5517614B2 (ja) | 2006-07-13 | 2014-06-11 | アキリオン ファーマシューティカルズ，インコーポレーテッド | ウイルス複製阻害剤としての４−アミノ−４−オキソブタノイルペプチド類 |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2008070358A2 (en) * | 2006-11-16 | 2008-06-12 | Phenomix Corporation | N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2679563A1 (en) * | 2007-01-08 | 2008-07-17 | Phenomix Corporation | Macrocyclic hepatitis c protease inhibitors |
| MX2009008540A (es) * | 2007-02-08 | 2009-08-18 | Tibotec Pharm Ltd | Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina. |
| WO2008096002A1 (en) * | 2007-02-08 | 2008-08-14 | Tibotec Pharmaceuticals Ltd. | Hcv inhibiting macrocyclic phosphonates and amidophosphates |
| US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
| US8304385B2 (en) | 2007-11-14 | 2012-11-06 | Enanta Pharmaceuticals, Inc. | Macrocyclic tetrazolyl hepatitis C serine protease inhibitors |
| US8273709B2 (en) | 2007-12-14 | 2012-09-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic HCV serine protease inhibitors |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| JP5490778B2 (ja) | 2008-03-20 | 2014-05-14 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｃ型肝炎ウイルス阻害剤としてのフッ素化大環状化合物 |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2300491B1 (en) | 2008-05-29 | 2016-01-06 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| ES2527166T3 (es) | 2008-12-10 | 2015-01-21 | Achillion Pharmaceuticals, Inc. | Nuevos péptidos de 4-amino-4-oxobutanoílo como inhibidores de la replicación viral |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2758072A1 (en) * | 2009-04-08 | 2010-10-14 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| CN101987825B (zh) * | 2009-07-31 | 2014-04-02 | 上海开拓者医药发展有限公司 | 一种2-氨基-3-甲基-4-甲氧基苯乙酮的制备方法 |
| WO2011017389A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
| US8937041B2 (en) | 2010-12-30 | 2015-01-20 | Abbvie, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
| EP2658858A4 (en) | 2010-12-30 | 2014-06-25 | Enanta Pharm Inc | MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE |
| US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2013106631A1 (en) | 2012-01-11 | 2013-07-18 | Abbvie Inc. | Processes for making hcv protease inhibitors |
| BR112015007887A2 (pt) | 2012-10-08 | 2017-07-04 | Abbvie Inc | compostos úteis para produzir inibidores hcv protease |
| SI2909205T1 (sl) | 2012-10-19 | 2017-02-28 | Bristol-Myers Squibb Company | 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij |
| WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014137869A1 (en) | 2013-03-07 | 2014-09-12 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2970195B1 (en) | 2013-03-14 | 2017-08-02 | Achillion Pharmaceuticals, Inc. | Processes for producing sovaprevir |
| US9085607B2 (en) | 2013-03-15 | 2015-07-21 | Achillion Pharmaceuticals, Inc. | ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof |
| WO2014145507A1 (en) | 2013-03-15 | 2014-09-18 | Achillion Pharmaceuticals, Inc. | A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof |
| KR20160005686A (ko) | 2013-03-15 | 2016-01-15 | 아칠리온 파르마세우티칼스 인코포레이티드 | 소바프레비르 다형체들 및 이의 제조 방법 |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| MA41812A (fr) * | 2015-03-27 | 2018-01-30 | Janssen Pharmaceuticals Inc | Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT727419E (pt) | 1992-12-29 | 2002-08-30 | Abbott Lab | Compostos intermediarios para a preparacao de inibidores da protease retroviral |
| IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
| US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
| US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| CN1116288C (zh) | 1996-04-23 | 2003-07-30 | 沃泰克斯药物股份有限公司 | 用作肌苷－5'－一磷酸脱氢酶抑制剂的脲衍生物 |
| HU227742B1 (en) | 1996-10-18 | 2012-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| PT966465E (pt) | 1997-03-14 | 2003-11-28 | Vertex Pharma | Inibidores do enzima imfdh |
| WO1999007734A2 (en) | 1997-08-11 | 1999-02-18 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
| GB9818731D0 (en) * | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
| CZ301802B6 (cs) | 1999-03-19 | 2010-06-30 | Vertex Pharmaceuticals Incorporated | Deriváty mocoviny jako inhibitory IMPDH a farmaceutické prostredky s jejich obsahem |
| UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| TW200403236A (en) * | 2002-04-11 | 2004-03-01 | Vertex Pharma | Inhibitors or serine proteases, particularly HCV NS3-NS4A protease |
| EP1629000B1 (en) * | 2003-04-16 | 2009-02-18 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus |
| US7125845B2 (en) * | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
| ES2336009T3 (es) | 2004-01-30 | 2010-04-07 | Medivir Ab | Inhibidores de la ns-3 serina proteasa del vhc. |
| KR101381387B1 (ko) * | 2005-07-29 | 2014-04-11 | 메디비르 아베 | Ｃ형 간염 바이러스의 마크로사이클릭 억제제 |
| PE20070343A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Inhibidores macrociclicos del virus de la hepatitis c |
-
2006
- 2006-07-19 JO JO2006237A patent/JO2768B1/en active
- 2006-07-26 PE PE2006000917A patent/PE20070221A1/es not_active Application Discontinuation
- 2006-07-28 AP AP2008004305A patent/AP2473A/xx active
- 2006-07-28 JP JP2008523375A patent/JP5426163B2/ja not_active Expired - Fee Related
- 2006-07-28 AU AU2006274858A patent/AU2006274858B2/en not_active Ceased
- 2006-07-28 EA EA200800484A patent/EA014646B1/ru not_active IP Right Cessation
- 2006-07-28 SI SI200631129T patent/SI1912995T1/sl unknown
- 2006-07-28 US US11/995,573 patent/US7989471B2/en not_active Expired - Fee Related
- 2006-07-28 MX MX2008001395A patent/MX2008001395A/es active IP Right Grant
- 2006-07-28 CA CA2617095A patent/CA2617095C/en not_active Expired - Fee Related
- 2006-07-28 SG SG201005107-6A patent/SG163613A1/en unknown
- 2006-07-28 WO PCT/EP2006/064813 patent/WO2007014919A1/en active Application Filing
- 2006-07-28 AR ARP060103306A patent/AR055104A1/es unknown
- 2006-07-28 BR BRPI0614670-8A patent/BRPI0614670A2/pt not_active Application Discontinuation
- 2006-07-28 KR KR1020087003833A patent/KR101074673B1/ko not_active IP Right Cessation
- 2006-07-28 GT GT200600341A patent/GT200600341A/es unknown
- 2006-07-28 UY UY29705A patent/UY29705A1/es unknown
- 2006-07-28 CN CN200680027654.7A patent/CN101233137B/zh not_active Expired - Fee Related
- 2006-07-28 TW TW095127588A patent/TWI412534B/zh not_active IP Right Cessation
- 2006-07-28 DK DK06764264.5T patent/DK1912995T3/da active
- 2006-07-28 MY MYPI20063671 patent/MY152153A/en unknown
- 2006-07-28 EP EP06764264A patent/EP1912995B1/en active Active
- 2006-07-28 NZ NZ564541A patent/NZ564541A/en not_active IP Right Cessation
- 2006-07-28 AT AT06764264T patent/ATE517902T1/de active
- 2006-07-29 SV SV2006002639A patent/SV2008002639A/es unknown
-
2007
- 2007-12-20 IL IL188283A patent/IL188283A/en not_active IP Right Cessation
-
2008
- 2008-02-29 NO NO20081071A patent/NO20081071L/no not_active Application Discontinuation
- 2008-06-18 HK HK08106769.8A patent/HK1116772A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR055104A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
| AR055361A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
| AR057703A1 (es) | INHIBIDORES MACROCíCLICOS DEL VIRUS DE LA HEPATITIS C. PROCESO DE PREPARACIoN Y COMPOSICIONES FARMACÉUTICAS. | |
| AR055360A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| AR088449A1 (es) | Benzilindazoles sustituidos | |
| AR094621A1 (es) | Compuestos y composiciones farmacéuticas para el tratamiento de infecciones virales | |
| CO5640152A2 (es) | Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c | |
| AR054882A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
| AR063653A1 (es) | Inhibidores del virus de la hepatitis c | |
| PE20160751A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| ES2590504T3 (es) | N-ciclilamidas como nematicidas | |
| AR038703A1 (es) | Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3 | |
| ES2722409T3 (es) | Moduladores de ROR gamma (RORy) | |
| PE20040940A1 (es) | Derivados de 3-cicloalquil-indol como inhibidores de la polimerasa del virus de hepatitis c | |
| AR087624A1 (es) | Derivados fenilicos y/o heterociclicos nitrogenados de sulfuro y sulfoxido utiles como pesticidas | |
| AR091272A1 (es) | Pirazolopirimidona y pirazolopiridona como inhibidores de tanquirasa | |
| AR067327A1 (es) | Derivados de piperidina / piperazina | |
| AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| CO6140056A2 (es) | Compuestos amino -5-4(difluorometoxi)fenil sustituido-5-fenilimidazolona como inhibidores de beta -secretasa | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
| AR108778A1 (es) | Compuestos antibacterianos | |
| AR075531A1 (es) | Derivados de piperazin-ciclopropil benzamidas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central, tales como alzheimer y esquizofrenia, entre otros | |
| AR075975A1 (es) | Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintetasa quinasa 3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |